Home  »  Industry   »  A peek at Arcus Biosciences Inc. (RCUS): Who has i...

A peek at Arcus Biosciences Inc. (RCUS): Who has invested in It?

Arcus Biosciences Inc. (NYSE: RCUS) is -17.99% lower on its value in year-to-date trading and has touched a low of $15.70 and a high of $39.75 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RCUS stock was last observed hovering at around $17.17 in the last trading session, with the day’s loss setting it -0.21% off its average median price target of $40.00 for the next 12 months. It is also 75.77% off the consensus price target high of $70.00 offered by 12 analysts, but current levels are 26.26% higher than the price target low of $23.00 for the same period.

Currently trading at $16.96, the stock is -6.80% and -13.74% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.71 million and changing -1.22% at the moment leaves the stock -31.11% off its SMA200. RCUS registered -45.88% loss for a year compared to 6-month loss of -32.38%.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".

Sponsored

The stock witnessed a -14.86% gain in the last 1 month and extending the period to 3 months gives it a -45.97%, and is -4.61% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.99% over the week and 4.93% over the month.

Arcus Biosciences Inc. (RCUS) has around 500 employees, a market worth around $1.24B and $112.00M in sales. Distance from 52-week low is 8.03% and -57.33% from its 52-week high. The company has generated returns on investments over the last 12 months (-42.80%).

Arcus Biosciences Inc. (RCUS) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Arcus Biosciences Inc. (RCUS) is a “Buy”. 12 analysts offering their recommendations for the stock have an average rating of 1.80, where 2 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.

Arcus Biosciences Inc. is expected to release its quarterly report on 05/08/2023.The EPS is expected to shrink by -619.20% this year

Arcus Biosciences Inc. (RCUS) Top Institutional Holders

The shares outstanding are 72.74M, and float is at 51.46M with Short Float at 14.51%.

Arcus Biosciences Inc. (RCUS) Insider Activity

A total of 19 insider transactions have happened at Arcus Biosciences Inc. (RCUS) in the last six months, with sales accounting for 13 and purchases happening 6 times. The most recent transaction is an insider sale by Jarrett Jennifer, the company’s Chief Operating Officer. SEC filings show that Jarrett Jennifer sold 1,600 shares of the company’s common stock on Jan 27 at a price of $23.52 per share for a total of $37632.0. Following the sale, the insider now owns 0.41 million shares.

Arcus Biosciences Inc. disclosed in a document filed with the SEC on Jan 26 that Jarrett Jennifer (Chief Operating Officer) sold a total of 300 shares of the company’s common stock. The trade occurred on Jan 26 and was made at $23.56 per share for $7068.0. Following the transaction, the insider now directly holds 0.42 million shares of the RCUS stock.

Still, SEC filings show that on Dec 16, Jarrett Jennifer (Chief Operating Officer) disposed off 16,482 shares at an average price of $30.75 for $0.51 million. The insider now directly holds 147,609 shares of Arcus Biosciences Inc. (RCUS).

Arcus Biosciences Inc. (RCUS): Who are the competitors?

The company’s main competitors (and peers) include Merck & Co. Inc. (MRK) that is trading 38.38% up over the past 12 months and Pfizer Inc. (PFE) that is -22.91% lower over the same period.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts